Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Regeneron Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Stock quotes in this article: REGN 

Regeneron Pharmaceuticals Inc. (REGN)

Q4 2011 Earnings Call

February 13, 2012 8:30 am ET

Executives

Dr. Leonard Schleifer – President, Chief Executive Officer

Murray Goldberg – Chief Financial Officer

Robert Terifay – Senior Vice President, Commercial

Dr. Michael Aberman – Vice President, Strategy and Investor Relations

Analysts

Jim Birchenough – BMO Capital

Jason Kantor – RBC Capital Markets

Josh Schimmer – Leerink Swann

Alethia Young – Deutsche Bank

Chris Raymond – Robert W. Baird

Steve Byrne – Bank of America

Biren Amin – Jefferies

Mani Mohindru – ThinkEquity

Yaron Werber - Citigroup

Geoff Meacham – JP Morgan

Phil Nadeau – Cowen & Company

Presentation

Operator

Good morning ladies and gentlemen. Welcome to the Regeneron Pharmaceuticals Conference Call to discuss the fourth quarter and full-year 2011 financial results. My name is Latoya and I’ll be your coordinator for today. At this time, all participants are in a listen-only mode. We will conduct a question and answer session towards the end of the call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Dr. Aberman, Vice President of Strategy and Investor Relations for Regeneron. Please proceed, Dr. Aberman.

Dr. Michael Aberman

Thank you very much. Good morning and welcome to Regeneron Pharmaceuticals’ Fourth Quarter and Full-Year 2011 conference call. An archive of this webcast will be available on our website under Events and Presentations for 30 days.

Joining me on the call today is Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; Murray Goldberg, Chief Financial Officer; and Robert Terifay, Senior Vice President, Commercial. After our prepared remarks, we will open the call for questions and answers.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,344.57 9.29 0.06%
NASDAQ 3,489.33 -7.10 -0.20%
S&P 500 1,664.75 -1.54 -0.09%
US 10 Yr 1.980% +0.015

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs